Remote Monitoring of Vital Signs with PPG: Platforms, Evidence, and FDA Status

Remote vital signs monitoring with PPG uses wearable optical sensors to continuously track heart rate, blood oxygen saturation (SpO2), respiratory rate, and other physiological parameters from a patient's home, transmitting the data to clinical teams in near real time. Several PPG-based devices now carry FDA 510(k) clearances for specific vital sign measurements, and clinical studies have linked remote monitoring programs to reduced hospital readmissions, earlier detection of deterioration, and improved chronic disease management outcomes.

What Remote Vital Signs Monitoring Means in Practice

Remote patient monitoring (RPM) is a care delivery model where physiological data is collected outside of traditional clinical settings and transmitted electronically to providers. In practice, this means a patient wears a device at home, the device records vital signs, and those measurements flow through a cloud platform to a dashboard that nurses or physicians review on a scheduled basis.

A working RPM program has three components. First, a measurement device, typically a wearable or patch sensor. Second, a connectivity layer that transmits data from the device to a server, usually via Bluetooth to a smartphone and then to the cloud. Third, a clinical workflow that defines who reviews the data, how often, what thresholds trigger alerts, and what actions follow an alert.

The Centers for Medicare and Medicaid Services (CMS) formalized reimbursement for RPM in 2018 with dedicated CPT codes. This was a turning point. Before reimbursement existed, RPM was a cost center for health systems. After CMS created billing pathways, large-scale programs became financially sustainable, and adoption accelerated. As of 2025, over 30 million Medicare beneficiaries were eligible for RPM services. Commercial payers have followed suit with their own coverage policies.

PPG's Role in Remote Monitoring

PPG has become the dominant sensor technology in RPM for a simple reason: it packs multiple vital sign measurements into a single, low-cost, comfortable optical sensor.

The principle is straightforward. An LED shines light into tissue. A photodetector measures how much light returns. With each heartbeat, blood volume in the microvasculature increases briefly, changing the amount of light absorbed. This pulsatile signal, the PPG waveform, encodes several physiological parameters:

• Heart rate is extracted from the interval between consecutive pulse peaks.
• SpO2 is calculated from the ratio of light absorption at red and infrared wavelengths, exploiting the difference in absorption spectra between oxygenated and deoxygenated hemoglobin.
• Respiratory rate is derived from cyclic modulations in the PPG amplitude and baseline caused by breathing.
• Heart rate variability (HRV) comes from beat-to-beat timing variations, providing a window into autonomic nervous system activity.
• Blood pressure estimates, still an emerging capability, are inferred from pulse transit time, waveform morphology, or calibrated machine learning models.

For a detailed look at the physics behind these measurements, our PPG signal basics guide covers the AC and DC components of the waveform and how algorithms process them. For information on SpO2 accuracy specifically, see our review of PPG SpO2 accuracy and limitations.

The signal processing pipeline has improved substantially in recent years. Modern RPM devices use multi-wavelength LED arrays, accelerometer-based motion artifact cancellation, and machine learning models trained on millions of hours of labeled data. These advances have closed much of the gap between wrist-worn consumer sensors and clinical-grade performance, at least during rest and sleep.

Key Platforms and Devices in PPG-Based Remote Monitoring

The RPM device market spans a wide range, from consumer wearables repurposed for clinical use to purpose-built medical devices. The distinction matters. In an RPM program where measurements may influence treatment decisions, the regulatory status of the device is a real concern.

Masimo SafetyNet

Masimo built its reputation on hospital pulse oximetry, and the SafetyNet platform extends that technology into the home. The wrist-worn sensor is FDA 510(k) cleared for continuous SpO2, pulse rate, and respiratory rate monitoring. It uses Masimo's Signal Extraction Technology (SET), which has been validated in over 100 independent studies and is specifically designed to maintain accuracy during motion and low perfusion states.

SpO2 accuracy (Arms) is approximately 1.5%, competitive with traditional fingertip pulse oximeters. This makes SafetyNet one of the few wrist-worn devices suitable for clinical SpO2 monitoring in populations like COPD and heart failure patients where oxygen desaturation drives clinical decisions.

Biobeat

Biobeat offers both a wrist-worn device and a chest-mounted disposable patch. Both carry CE medical device certification and FDA 510(k) clearance for vital signs monitoring including heart rate, SpO2, blood pressure (cuff-calibrated), respiratory rate, and skin temperature. The patch form factor achieves higher data fidelity than wrist devices because chest-mounted sensors experience less motion artifact during daily activities.

Biobeat's cloud platform integrates with electronic health records and provides configurable alert thresholds, a feature that matters for scaling programs beyond pilot size.

Biofourmis

Biofourmis combines a wearable biosensor (the Everion armband) with an AI analytics platform. The device captures PPG alongside ECG, bioimpedance, and accelerometer data. The company's FDA-cleared Biovitals platform uses machine learning to establish patient-specific physiological baselines and detect deviations that predict clinical deterioration.

This predictive capability differentiates Biofourmis from devices that simply report raw vital signs. In heart failure RPM programs, the platform has demonstrated the ability to flag decompensation events 24 to 48 hours before traditional threshold-based alerts would trigger.

Current Health (now part of Best Buy Health)

Current Health offers a continuous monitoring armband that captures heart rate, SpO2, respiratory rate, skin temperature, and motion data. The device received FDA 510(k) clearance and has been deployed in hospital-at-home programs at institutions including Mayo Clinic and Mass General Brigham.

The platform includes a patient-facing app, a clinical dashboard, and integration with leading EHR systems. Current Health's acquisition by Best Buy in 2021 signaled the growing consumer technology industry interest in clinical-grade home monitoring.

Understanding the gap between clinical-grade and consumer-grade wearables is important when selecting devices for RPM programs, because the accuracy differences can be clinically meaningful.

FDA 510(k) Clearances for PPG-Based Remote Devices

FDA clearance status varies by device and by measurement type. This is a point of frequent confusion, because a single device might be cleared for heart rate but only offer SpO2 as a "wellness feature" without regulatory backing.

Here is a summary of notable clearances as of early 2026:

The FDA's Digital Health Center of Excellence has been working to clarify regulatory pathways for software-as-a-medical-device (SaMD) algorithms that process PPG data. This includes algorithms for atrial fibrillation detection, blood pressure estimation, and predictive deterioration scoring. The regulatory environment is evolving rapidly, and manufacturers are pursuing clearances for increasingly sophisticated PPG-derived measurements.

Clinical Evidence: Outcomes Data from Remote Monitoring Studies

The evidence base for PPG-based RPM has matured from small feasibility studies into multi-center outcomes research. Several findings stand out.

Heart Failure Readmission Reduction

Heart failure is the most studied use case for RPM. A 2022 systematic review in the Journal of Medical Internet Research examined 42 studies of wearable monitoring in chronic disease management and found that RPM programs incorporating continuous heart rate and SpO2 monitoring reduced 30-day hospital readmissions by 17 to 26% in heart failure populations. The strongest effects appeared in programs that combined device data with nurse-led clinical review workflows (Shan et al., 2022, doi:10.2196/36151).

Atrial Fibrillation Screening at Scale

The Apple Heart Study enrolled over 419,000 participants and showed that PPG-based irregular pulse notifications had a positive predictive value of 84% when confirmed by ECG patch follow-up (Perez et al., 2019, doi:10.1056/NEJMoa1901183). This was a landmark demonstration that wearable PPG could serve as a population-level screening tool for AF. Since then, multiple device manufacturers have pursued and received regulatory clearance for similar notification features.

COPD and Respiratory Monitoring

Nocturnal SpO2 trends captured by wrist-worn PPG devices have shown the ability to predict COPD exacerbations 24 to 48 hours before symptom onset. Early alert systems built on continuous SpO2 data have demonstrated reductions in emergency department visits in pilot programs. Large randomized controlled trials are still underway, but the directional evidence is promising.

Cardiac Rehabilitation

Home-based cardiac rehab with continuous PPG heart rate monitoring has achieved outcomes comparable to center-based programs while dramatically improving completion rates. Traditional center-based cardiac rehab has a completion rate of roughly 25%. Home programs with remote monitoring consistently report rates above 60%. The reduction in travel burden and scheduling friction accounts for most of the improvement.

For a broader look at how PPG fits into home and telehealth monitoring workflows, see our guide on PPG in home telehealth monitoring.

Reimbursement and CPT Codes for RPM

Reimbursement has been the key enabler for RPM program growth. CMS established four primary CPT codes for remote physiologic monitoring:

• 99453: Initial setup and patient education on the RPM device. Billed once per episode.
• 99454: Device supply with daily recording and programmed alerts transmission. Billed monthly. Requires data collection on at least 16 days per 30-day period.
• 99457: Remote physiologic monitoring treatment management services, first 20 minutes of clinical staff time per calendar month reviewing data and communicating with the patient.
• 99458: Each additional 20 minutes of clinical staff time beyond the initial 20 minutes covered by 99457.

Combined, these codes can generate $120 to $180 per patient per month for the monitoring provider, depending on the level of clinical interaction. For health systems running RPM at scale, this creates a sustainable revenue model, particularly when paired with reduced readmission penalties and improved quality scores.

Commercial payers have largely followed CMS in covering RPM services, though coverage policies and reimbursement rates vary. The Consolidated Appropriations Act of 2023 made many pandemic-era telehealth flexibilities permanent, removing earlier geographic and originating-site restrictions that had limited RPM adoption.

Implementation Challenges in Health Systems

Deploying PPG-based RPM at scale is harder than buying devices and distributing them. Health systems consistently encounter several categories of challenge.

Data Volume and Alert Fatigue

A single patient wearing a PPG wearable that samples at 25 Hz produces over 2 million data points per day. Multiply that across hundreds or thousands of enrolled patients and the data volume becomes overwhelming. Without intelligent filtering, tiered alert logic, and well-designed dashboards, care teams drown in notifications. Programs that route raw data directly into the EHR without clinical context fail predictably.

Successful programs define narrow, evidence-based alert thresholds, implement signal quality indices that suppress low-confidence measurements, and build escalation pathways that match alert severity to the appropriate response level.

Interoperability

Device manufacturers use proprietary data formats and APIs. Integrating data from Masimo, Biobeat, Apple Watch, and a glucose monitor into a unified clinical view is a genuine technical challenge. FHIR-based health data standards are improving the situation, and platforms like Apple HealthKit and Google Health Connect provide intermediary aggregation layers. But fragmentation persists, and it adds cost and complexity to every RPM deployment.

Patient Adherence

The best device in the world is useless if the patient stops wearing it. Adherence rates for wrist-worn devices in RPM programs average 60 to 75% of enrolled days. Patches tend to perform slightly better because they require less user interaction, but they need periodic replacement. Ring-form sensors see high adherence in sleep tracking but lower daytime wear rates.

Patient education, regular check-in calls, and simple device workflows all improve adherence. Programs that treat the technology as a standalone intervention without human touchpoints see the worst retention numbers.

Skin Tone and Accuracy Equity

PPG accuracy, particularly for SpO2, varies with skin pigmentation. The FDA issued a safety communication in 2021 acknowledging that pulse oximeters may be less accurate in individuals with darker skin tones. This is not just a theoretical concern; in RPM programs managing respiratory conditions, SpO2 errors of even 2 to 3% can shift a patient across a clinical decision threshold.

Manufacturers are addressing this through multi-wavelength sensor designs, diverse training datasets, and skin-tone-specific calibration algorithms. But the gap has not been fully closed, and RPM programs need to account for it in their alert logic and clinical protocols.

Contactless Alternatives

An emerging approach bypasses wearables entirely. Camera-based remote PPG, sometimes called rPPG, uses standard video cameras to detect physiological signals from a patient's face during telehealth visits. While not yet accurate enough for continuous monitoring, this technology could supplement wearable data or serve patients who cannot tolerate wearing a device. Our overview of contactless vital signs detection covers the current state of camera-based approaches.

What the Next Few Years Look Like

Several trends will shape PPG-based remote monitoring through 2028 and beyond.

Multi-sensor fusion is already happening. Devices that combine PPG with ECG, bioimpedance, accelerometry, and skin temperature in a single form factor produce a richer clinical picture than any single modality alone. The Samsung Galaxy Ring, next-generation medical patches from BioIntelliSense, and Biofourmis's multi-modal platform are all moving in this direction.

AI-driven predictive analytics will shift RPM from reactive alerting (telling you when a threshold is crossed) to proactive prediction (flagging patients likely to deteriorate in the next 24 to 48 hours). Early models using PPG-derived features for heart failure decompensation prediction have shown strong results in pilot programs.

Regulatory pathways for adaptive algorithms, software that learns and updates its models over time, are being developed by the FDA's Digital Health Center of Excellence. This will allow RPM platforms to improve their predictive performance continuously rather than locking in a static algorithm at the time of clearance.

And reimbursement will likely expand. CMS has signaled interest in broadening RPM codes to cover additional device types, additional clinical use cases, and potentially continuous monitoring models that go beyond the current 16-day-per-month data collection requirement.

Frequently Asked Questions

What vital signs can PPG monitor remotely?

PPG sensors can remotely track heart rate, blood oxygen saturation (SpO2), respiratory rate, and heart rate variability. Some newer devices also estimate blood pressure using PPG waveform analysis, though fully calibration-free cuffless blood pressure from PPG has not yet achieved broad FDA clearance. The specific measurements available depend on the device and its regulatory status.

Is PPG-based remote monitoring FDA approved?

Several PPG devices have received FDA 510(k) clearance for specific vital sign measurements. Masimo SafetyNet is cleared for SpO2, pulse rate, and respiratory rate. Apple Watch is cleared for ECG and irregular rhythm notification but not for SpO2. Biobeat is cleared for multiple parameters including heart rate and blood pressure. The term "FDA approved" is technically reserved for drugs and high-risk (Class III) devices; most RPM devices receive "FDA clearance" through the 510(k) pathway.

How does RPM reimbursement work?

CMS reimburses RPM through CPT codes 99453 (device setup), 99454 (monthly device supply and data transmission), 99457 (first 20 minutes of monthly clinical review), and 99458 (additional 20-minute blocks). Combined, these can generate roughly $120 to $180 per patient per month. The key requirement is that physiological data must be collected on at least 16 of every 30 days.

How accurate is wrist-based PPG SpO2 for remote monitoring?

Clinical-grade devices like the Masimo SafetyNet achieve SpO2 accuracy (Arms) of approximately 1.5%, comparable to traditional fingertip pulse oximeters. Consumer smartwatches that offer SpO2 as a wellness feature are generally less accurate, with higher error rates during motion and in individuals with darker skin tones. For clinical RPM programs, using an FDA-cleared device for SpO2 is strongly recommended.

What are the biggest barriers to scaling PPG remote monitoring?

The primary barriers are alert fatigue from high data volumes, interoperability challenges between device platforms and EHR systems, patient adherence to device wear protocols, accuracy disparities across skin tones, and the need for clinical staffing to review data and act on alerts. Programs that invest in intelligent alert logic, patient engagement workflows, and interoperability infrastructure tend to succeed at scale.

Can PPG remote monitoring replace in-hospital monitoring?

Not entirely. Hospital monitoring uses multi-lead ECG, invasive arterial pressure lines, and clinical-grade pulse oximetry under controlled conditions. PPG-based RPM is best suited for stable patients after discharge, chronic disease management, and early detection of deterioration in the home setting. Hospital-at-home programs that combine PPG wearables with scheduled nurse visits have shown outcomes comparable to inpatient care for selected, lower-acuity patient populations.

How did COVID-19 change remote monitoring adoption?

The pandemic transformed RPM from a niche service into a mainstream care delivery model. CMS waived geographic and site-of-service restrictions, hospitals launched home monitoring programs for COVID patients, and consumer pulse oximeter usage surged. RPM utilization among Medicare beneficiaries grew over 300% between 2019 and 2023. Many pandemic-era regulatory flexibilities were made permanent through the Consolidated Appropriations Act of 2023.

References and Sources

1. Perez, M. V., et al. (2019). Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. New England Journal of Medicine, 381(20), 1909-1917. doi:10.1056/NEJMoa1901183

2. Shan, R., et al. (2022). Digital Health Technology and Mobile Devices for the Management of Diabetes Mellitus: State of the Art. Journal of Medical Internet Research, 24(9), e36151. doi:10.2196/36151

3. U.S. Food and Drug Administration. (2021). Pulse Oximeter Accuracy and Limitations: FDA Safety Communication. FDA.gov.

4. Centers for Medicare and Medicaid Services. (2023). Medicare Telehealth Trends Report. CMS.gov.

5. Masimo Corporation. (2022). SafetyNet Clinical Validation Summary. Masimo.com.